JP2015534990A - 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法 - Google Patents

誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法 Download PDF

Info

Publication number
JP2015534990A
JP2015534990A JP2015538124A JP2015538124A JP2015534990A JP 2015534990 A JP2015534990 A JP 2015534990A JP 2015538124 A JP2015538124 A JP 2015538124A JP 2015538124 A JP2015538124 A JP 2015538124A JP 2015534990 A JP2015534990 A JP 2015534990A
Authority
JP
Japan
Prior art keywords
aryl
compound
disease
alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015538124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015534990A5 (OSRAM
Inventor
マイケル パタネ
マイケル パタネ
Original Assignee
イージェニックス インコーポレイテッド
イージェニックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イージェニックス インコーポレイテッド, イージェニックス インコーポレイテッド filed Critical イージェニックス インコーポレイテッド
Publication of JP2015534990A publication Critical patent/JP2015534990A/ja
Publication of JP2015534990A5 publication Critical patent/JP2015534990A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015538124A 2012-10-22 2013-10-22 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法 Pending JP2015534990A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261716987P 2012-10-22 2012-10-22
US61/716,987 2012-10-22
US201261735458P 2012-12-10 2012-12-10
US61/735,458 2012-12-10
PCT/US2013/066041 WO2014066304A1 (en) 2012-10-22 2013-10-22 Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e

Publications (2)

Publication Number Publication Date
JP2015534990A true JP2015534990A (ja) 2015-12-07
JP2015534990A5 JP2015534990A5 (OSRAM) 2016-12-08

Family

ID=50545165

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015538124A Pending JP2015534990A (ja) 2012-10-22 2013-10-22 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法

Country Status (7)

Country Link
US (1) US9409901B2 (OSRAM)
EP (1) EP2909203A4 (OSRAM)
JP (1) JP2015534990A (OSRAM)
AU (1) AU2013334860B2 (OSRAM)
CA (1) CA2888889A1 (OSRAM)
IL (1) IL238415B (OSRAM)
WO (1) WO2014066304A1 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019536785A (ja) * 2016-11-30 2019-12-19 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法
JP2022545987A (ja) * 2019-09-03 2022-11-01 ソバージェン カンパニー，リミテッド ｅＩＦ４Ｅ阻害剤を含むｅＩＦ４Ｅ活性増加に関わる状態の診断または治療用組成物
JP2023515888A (ja) * 2020-03-03 2023-04-14 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108349962A (zh) * 2015-06-01 2018-07-31 班塔姆制药有限责任公司 取代的吡唑和吡咯化合物以及使用其用于抑制翻译起始和治疗与其相关的疾病和病症的方法
CA3082011A1 (en) 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Methods of using substituted pyrazole and pyrrole compounds and for treatment of hyperproliferative diseases
WO2021067752A1 (en) * 2019-10-04 2021-04-08 Yale University Targeting cap-dependent translation to reduce seizures in mtor disorders

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007533752A (ja) * 2004-04-20 2007-11-22 トランス　テック　ファーマ，インコーポレイテッド メラノコルチン受容体の調節因子としての置換チアゾール及びピリミジン誘導体
JP2008528502A (ja) * 2005-01-21 2008-07-31 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ タンパク質合成の調節
JP2009543835A (ja) * 2006-07-14 2009-12-10 グラクソ グループ リミテッド インドール化合物
JP2009543836A (ja) * 2006-07-14 2009-12-10 グラクソ グループ リミテッド インドール化合物
JP2010508278A (ja) * 2006-10-31 2010-03-18 シェーリング コーポレイション アニリノピペラジン誘導体およびアニリノピペラジン誘導体を使用する方法
JP2010535201A (ja) * 2007-07-31 2010-11-18 シェーリング コーポレイション 抗癌治療としての抗有糸分裂薬およびオーロラキナーゼ阻害薬
WO2012006068A2 (en) * 2010-06-28 2012-01-12 President And Fellows Of Harvard College Compounds for the inhibition of cellular proliferation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007533752A (ja) * 2004-04-20 2007-11-22 トランス　テック　ファーマ，インコーポレイテッド メラノコルチン受容体の調節因子としての置換チアゾール及びピリミジン誘導体
JP2008528502A (ja) * 2005-01-21 2008-07-31 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ タンパク質合成の調節
JP2009543835A (ja) * 2006-07-14 2009-12-10 グラクソ グループ リミテッド インドール化合物
JP2009543836A (ja) * 2006-07-14 2009-12-10 グラクソ グループ リミテッド インドール化合物
JP2010508278A (ja) * 2006-10-31 2010-03-18 シェーリング コーポレイション アニリノピペラジン誘導体およびアニリノピペラジン誘導体を使用する方法
JP2010535201A (ja) * 2007-07-31 2010-11-18 シェーリング コーポレイション 抗癌治療としての抗有糸分裂薬およびオーロラキナーゼ阻害薬
WO2012006068A2 (en) * 2010-06-28 2012-01-12 President And Fellows Of Harvard College Compounds for the inhibition of cellular proliferation

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019536785A (ja) * 2016-11-30 2019-12-19 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法
JP7373992B2 (ja) 2016-11-30 2023-11-06 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニー 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法
JP2022545987A (ja) * 2019-09-03 2022-11-01 ソバージェン カンパニー，リミテッド ｅＩＦ４Ｅ阻害剤を含むｅＩＦ４Ｅ活性増加に関わる状態の診断または治療用組成物
JP2023515888A (ja) * 2020-03-03 2023-04-14 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用

Also Published As

Publication number Publication date
IL238415B (en) 2018-04-30
EP2909203A1 (en) 2015-08-26
CA2888889A1 (en) 2014-05-01
AU2013334860B2 (en) 2018-02-15
US20150274717A1 (en) 2015-10-01
IL238415A0 (en) 2015-06-30
WO2014066304A1 (en) 2014-05-01
EP2909203A4 (en) 2016-04-06
AU2013334860A1 (en) 2015-05-14
US9409901B2 (en) 2016-08-09

Similar Documents

Publication Publication Date Title
ES2820827T3 (es) Formas sólidas de un compuesto modulador de quinasas
US10316032B2 (en) Solid forms of a compound for modulating kinases
CN111770914B (zh) 作为神经激肽-1受体拮抗剂的化合物及其用途
EP2813498B1 (en) Compounds for Alzheimer's disease
CN103119047B (zh) 三环类蛋白酶体活性增强化合物
JP2015534990A (ja) 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法
EP3570940B1 (en) Pridopidine for use in the treatment of fragile x syndrome
KR20160113287A (ko) 단백질 응집 저해제로서의 헤테로아릴 아미드
RU2736123C1 (ru) Производные 2-аминохиназолина в качестве ингибиторов p70s6 киназы
CA3173679A1 (en) Inhibitors of the peptidyl-prolyl cis/trans isomerase (pin1) and uses thereof
US20220395577A1 (en) Methods and materials for modulating nrf2 pathway
WO2014183673A1 (zh) 阿那格雷及其衍生物的抗肿瘤用途
US11896589B2 (en) Diazinyl amino acridines and medical uses thereof
CN115515682B (zh) 用于治疗神经退行性疾病和线粒体疾病的组合物及其使用方法
TW202116301A (zh) 藥物組合及其用途
JPWO2018186366A1 (ja) 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤
CN114828856B (zh) 以稠合嘧啶化合物为有效成分的治疗剂
CN114901665B (zh) 三唑并三嗪衍生物在治疗疾病中的用途
WO2024167856A1 (en) Method for treating nervous system disorders using boldine and analogs thereof
AU2023232568A1 (en) Dual lsd1/hdac inhibitors
HK40086209A (zh) 用於治疗神经退行性疾病和线粒体疾病的组合物及其使用方法
HK40086209B (zh) 用於治疗神经退行性疾病和线粒体疾病的组合物及其使用方法
HK40016661B (en) Pridopidine for use in the treatment of fragile x syndrome
HK40016661A (en) Pridopidine for use in the treatment of fragile x syndrome
JPWO2016084870A1 (ja) アシルアミノフェニル基を有する化合物及びその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161024

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20161024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170807

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180613

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190128